Marshall Wace LLP Has $1.72 Million Stock Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Marshall Wace LLP decreased its stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 4.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 86,762 shares of the company’s stock after selling 3,809 shares during the period. Marshall Wace LLP owned approximately 0.12% of Kiniksa Pharmaceuticals worth $1,716,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Geode Capital Management LLC boosted its stake in Kiniksa Pharmaceuticals by 2.0% during the fourth quarter. Geode Capital Management LLC now owns 492,630 shares of the company’s stock worth $9,744,000 after buying an additional 9,654 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in Kiniksa Pharmaceuticals by 138.9% during the fourth quarter. JPMorgan Chase & Co. now owns 477,800 shares of the company’s stock worth $9,451,000 after buying an additional 277,827 shares in the last quarter. Peregrine Capital Management LLC boosted its stake in Kiniksa Pharmaceuticals by 1.8% during the fourth quarter. Peregrine Capital Management LLC now owns 244,043 shares of the company’s stock worth $4,827,000 after buying an additional 4,361 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in Kiniksa Pharmaceuticals during the fourth quarter worth $3,955,000. Finally, Hennion & Walsh Asset Management Inc. boosted its stake in Kiniksa Pharmaceuticals by 1.9% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 199,525 shares of the company’s stock worth $3,947,000 after buying an additional 3,673 shares in the last quarter. Institutional investors and hedge funds own 53.95% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the stock. Wedbush reiterated an “outperform” rating and set a $34.00 price target on shares of Kiniksa Pharmaceuticals in a research note on Wednesday, April 16th. Citigroup started coverage on Kiniksa Pharmaceuticals in a report on Thursday, March 13th. They set a “buy” rating and a $40.00 price objective for the company. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $37.17.

Insider Activity at Kiniksa Pharmaceuticals

In related news, CAO Michael R. Megna sold 9,051 shares of Kiniksa Pharmaceuticals stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $22.45, for a total value of $203,194.95. Following the completion of the sale, the chief accounting officer now directly owns 26,528 shares in the company, valued at $595,553.60. This trade represents a 25.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Ross Moat sold 18,259 shares of the business’s stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $20.29, for a total value of $370,475.11. Following the transaction, the insider now owns 9,415 shares of the company’s stock, valued at $191,030.35. The trade was a 65.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 110,025 shares of company stock valued at $2,372,610 over the last ninety days. 54.57% of the stock is owned by insiders.

Kiniksa Pharmaceuticals Stock Performance

Shares of NASDAQ KNSA opened at $21.47 on Tuesday. The stock has a market cap of $1.56 billion, a PE ratio of -153.35 and a beta of 0.31. The business has a fifty day moving average of $21.19 and a two-hundred day moving average of $21.28. Kiniksa Pharmaceuticals, Ltd. has a 52-week low of $17.38 and a 52-week high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.06). Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The business had revenue of $122.50 million during the quarter, compared to the consensus estimate of $123.42 million. During the same period in the prior year, the firm earned $0.35 earnings per share. The business’s quarterly revenue was up 46.9% compared to the same quarter last year. Analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current year.

Kiniksa Pharmaceuticals Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.